01
Conditions and medicines
A clinical reason, current conditions, medicines and whether oral treatment is feasible are reviewed.
IV Supportive Treatments · Physician-Led Assessment · Istanbul
Indication · Ingredient · Infusion safety
IV Supportive Treatments
Intravenous delivery is a route, not a wellness category. A defined clinical rationale, exact product identity, sterile preparation, compatibility, venous safety and monitoring come before any infusion.
No detox, immunity, beauty, energy, anti-ageing, prevention or disease-treatment promise is made, and IV delivery is not assumed to be superior to oral care.
Physician-Led Orientation
Four levels before method selection
A reasoned sequence begins with the clinical question.
Online review can organise the question. Final suitability follows from in-person examination, the exact product or device and an individual risk–benefit assessment.
02
Laboratory findings and organ function
Allergies, laboratory context, organ function, fluid balance and previous reactions matter.
03
Product, dose and compatibility
Product, manufacturer, formulation, licence, batch and compatibility are verified.
04
Oral alternatives and stopping criteria
The oral route, infusion stopping criteria, delayed harms and emergency escalation are planned.
IV Support · 01–02
Single named products
Biological roles do not prove broad IV benefit.
Glutathione and vitamin C retain separate product, indication and organ-safety contexts.
01Single product
Glutathione Infusion
Antioxidant biology separated from IV clinical evidence and claims.
Decision boundaryOne existing canonical route; diagnosis, suitability and outcome remain individual.
Open Glutathione Infusion02Single product
NAD+ Infusion
Biochemistry separated from limited IV clinical evidence.
Decision boundaryOne existing canonical route; diagnosis, suitability and outcome remain individual.
Open NAD+ Infusion03Single product
Vitamin C Infusion
Nutrition, deficiency and high-dose IV contexts kept separate.
Decision boundaryOne existing canonical route; diagnosis, suitability and outcome remain individual.
Open Vitamin C InfusionIV Support · 03–05
NAD+ and variable mixtures
A product name or personalised label is not a standard protocol.
NAD+, Myers’ Cocktail and individualised infusion require exact identity, compatibility and evidence review.
04Variable mixture
Myers’ Cocktail Infusion
A variable mixture, not one standard licensed formula.
Decision boundaryOne existing canonical route; diagnosis, suitability and outcome remain individual.
Open Myers’ Cocktail Infusion05Clinical decision
Individualised IV Infusion
Personalisation limited by identity, compatibility and safety.
Decision boundaryOne existing canonical route; diagnosis, suitability and outcome remain individual.
Open Individualised IV InfusionQuality and Safety Framework
Four binding principles
Premium care means clearer selection, boundaries and follow-up.
Advertising language and package logic are replaced by product traceability, anatomy, proportionate alternatives and documented review.
01
Rationale before route
Do not use IV delivery as an automatic wellness advantage.
02
Identity before claim
Verify every product, formulation, licence, batch and preparation.
03
Risk before repetition
Infusion reaction, infection, phlebitis, extravasation, organ and interaction risks remain visible.
04
No treatment remains valid
Care, oral treatment, referral, observation or no intervention may be more proportionate.
Bağdat Caddesi · Istanbul
International patient pathway
Travel, examination and follow-up form one medical process.
The in-person appointment remains the decision point. Product records, early safety, return travel and local medical access are considered before treatment.
- 01
Organise the question
History and existing records prepare discussion without confirming treatment.
- 02
Assess in person
Rationale, products, organ context, interactions and venous safety are reviewed.
- 03
Keep traceability
Products, batches, preparation, route and observations are recorded.
- 04
Arrange escalation
Warning signs and local medical access are agreed before departure.
The Doctor Aslan Approach
Clinical rationale before infusion label
Supportive does not mean routine, harmless or proven.
Doctor Aslan separates the clinical rationale, exact product, licence, evidence, venous safety, alternatives and follow-up.
Assess first
Define the clinical reason and alternatives.
Verify identity
Keep every product and preparation traceable.
Limit the claim
No detox, immunity, energy, beauty or disease-treatment promise.
Accept no treatment
Withholding treatment remains a valid decision.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information about IV Supportive Treatments; no personal protocol or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01How is an option selected within IV Supportive Treatments?+
Selection begins with the diagnosis or clinical rationale, personal finding and aim. Only then are the exact products, formula, protocol, risks and alternatives compared.
02Is an online pre-assessment enough for a treatment decision?+
No. It can organise records and questions. Final diagnosis, suitability and planning are determined only after an in-person medical examination in Istanbul.
03Are an outcome or a fixed number of infusions promised?+
No. A responsible plan states the baseline, task, review point and criteria for continuing, changing or stopping.
04How is follow-up planned from abroad?+
The contact route, expected reactions, warning signs, local medical help and documented follow-up checks are agreed before treatment.
Next Step
Define the rationale · verify each product · plan monitoring